Abstract: The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent.

Abstract: Method of Measuring Residual Cancer and Predicting Patient Survival Disclosed is a method for determining survival and relapse of a patient undergoing therapy for a tumor by determining a residual cancer burden index based on the bidimensional diameters of a primary tumor bed of said tumor in a resection specimen, the proportion of the primary tumor bed area that contains invasive carcinoma, the number of regional lymph nodes containing metastatic carcinoma, the diameter of the largest metastasis in an regional lymph node; and the fractional reduction in lymph node size with each added positive lymph node.

Abstract: The present invention provides the identification of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose expression (either increased expression or decreased expression) correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent.